H4339
An Act relative to patient access to biomarker testing to provide appropriate therapy
Take action
Record your position on this measure.
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed House
- Passed Senate
- To Governor
- Became Law
Bill overview
This bill aims to improve patient access to biomarker testing, which can help doctors determine the most effective treatment for certain diseases, particularly cancer. It seeks to remove barriers that might prevent patients from receiving this testing and ultimately receiving more targeted and appropriate therapies. The legislation focuses on ensuring that biomarker testing is readily available and accessible to individuals who could benefit from it. It intends to align testing practices with treatment decisions.
Key provisions
- Expands access to biomarker testing for patients.
- Encourages healthcare providers to consider biomarker testing when determining treatment plans.
- Promotes the use of biomarker testing to guide treatment decisions.
- Aims to reduce disparities in access to biomarker testing based on socioeconomic status or geographic location.
Who is affected
- Patients with cancer
- Healthcare providers
- Insurance companies
- Pharmaceutical companies
- The healthcare system
Notable changes
- The bill seeks to integrate biomarker testing more directly into standard cancer treatment protocols.
- It may influence how insurance companies cover biomarker testing costs.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Joint Committee on Financial Services
Cosponsors
Adrian C. Madaro
Adrianne Pusateri Ramos
Amy Mah Sangiolo
Angelo J. Puppolo Jr.
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.
Bill H.4339 194th (Current)
An Act relative to patient access to biomarker testing to provide appropriate therapy
View Text Print Preview Download PDF
Bill Information
Bill Information
Sponsor: Joint Committee on Financial Services Status: Referred to House Committee on Ways and Means
Tabs
Bill History Cosponsors Committee Vote Fiscal Note Committee Summary
Bill History
Displaying 4 actions for Bill H.4339
| Date | Branch | Action |
| 7/31/2025 | House | Reported from the committee on Financial Services |
| 7/31/2025 | House | New draft of H1227 |
| 7/31/2025 | House | Reported favorably by committee and referred to the committee on Health Care Financing |
| 12/4/2025 | House | Committee recommended bill ought to pass and referred to the committee on House Ways and Means |
Similar Bills
H.1227 194th (Current)
An Act relative to patient access to biomarker testing to provide appropriate therapy
H.1074 193rd (2023 - 2024)
An Act relative to cancer patient access to biomarker testing to provide appropriate therapy
S.808 192nd (2021 - 2022)
An Act relative to cancer patient access to biomarker testing to provide appropriate therapy
S.809 194th (Current)
An Act relative to patient access to biomarker testing to provide appropriate therapy
S.689 193rd (2023 - 2024)
An Act relative to patient access to biomarker testing to provide appropriate therapy
The information contained in this website is for general information purposes only. The General Court provides this information as a public service and while we endeavor to keep the data accurate and current to the best of our ability, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.